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Abstract
Chronic P. aeruginosa infection is characterized by production of mucoid alginate and formation of microcolonies (biofilm) as
seen in the lungs of cystic fibrosis patients. Oxygen radicals produced by the inflammatory response polymorphonuclear leucocytes
induces the alginate production. The biofilm mode of growth is the survival strategy of environmental bacteria and alginate
biofilms are also protected against antibiotics and against the immune response in the lungs of the patient. Quorum sensing is
important for early and mature biofilm formation and also for the severity of the infection. The new knowledge of the mechanisms
involved in biofilm formation opens up new possibilities for therapeutic intervention strategies involving e.g. inhibitors of quorum
sensing.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The chronic P. aeruginosa lung infection in cystic
fibrosis (CF) is a biofilm (Fig. 1) w1x characterized by
1. the mucoid phenotype producing abundance of algin-
ate in vitro and in the patients w1x,
2. microcolonies surrounded by alginate in sputum and
in post-mortem investigations w2,1x,
3. the bacteria stay inside the mucus and grow under
anaerobic conditions using nitrate as electron acceptor
w3x,
4. the bacteria are not located on the epithelial cells w3x,
but they induce an endobronchiolitis without spread-
ing to the blood or to other organs w2x,
5. high levels of antibodies against alginate and other P.
aeruginosa antigens w1x,
6. resistance against the patients defence mechanisms
and against antibiotic treatment w1x.
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Oxygen radicals produced by the inflammatory
response polymorphonuclear leucocytes (PMNs) induc-
es mutations leading to the alginate production which is
so characteristic for P. aeruginosa biofilm infection in
CF w4x. Quorum sensing is also involved in mature
biofilm formation in vitro and in vivo w5x. The biofilm
mode of growth is the survival strategy of environmental
bacteria like P. aeruginosa and alginate biofilms are also
protected against antibiotics and against the immune
response in the lungs of the patient w1x. The tissue
damage is due to immune complex mediated chronic
inflammation dominated by PMNs leading to released
leukocyte proteases w1x.
2. Nature of P. aeruginosa biofilms and its resistance
to antibiotics
Bacteria growing in biofilms are much more resistant
to antibiotics compared to planktonic growing cells of
the same isolate: minimal inhibitory concentration
(MIC) and minimal bactericidal concentration can be
100–1000-fold greater in old biofilms whereas young
biofilms are less resistant. The same sensitivity as in the
planktonic bacteria is found if the bacteria from the
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Fig. 1. Development of P. aeruginosa biofilm in the bronchioles of CF patients w1–5,21,42–46x. Planctonic P. aeruginosa cells (PA) adhere
reversibly to the gel phase of airway lining fluid using the pole of their cells and the flagella and pili. Irreversible attachment occurs to the axis
of the bacterial cells which divide and form clusters and an early biofilm. This step involves type 4 pili and the lasIR encoded quorum sensing
system which major product is the signal molecule C12-HSL (N-(3-oxododecanoyl)-homoserine lactone. The production of alginate involves
mutations in the mucA gene of PA induced by oxygen radicals (OR) released together with elastase (ELA) (yellow clouds) from activated PMN.
Autolysing PMNs release DNA. Maturation of the biofilm with formation of water channels, pores and tower-like and mushroom-like structures
involves the rhlR encoded quorum sensing system which major product is the signal molecule C4-HSL (N-butanoylhomoserine lactone). Pieces
of biofilms and also planctonic PA cells are released from the surface of mature biofilms. Most of the PA biofilm is present in sputum and not
located on the epithelial cells of the respiratory airways and the biofilm is depleted of oxygen (ANAEROBIC). The tissue damage is due to the
inflammatory reaction aggravated by the antibody response to the components of the biofilm (immune complex mediated tissue damage).
resistant biofilm are liberated and reinvestigated. The
ordinary techniques used in the laboratory to determine
antibiotic susceptibility of planktonic growing bacteria
cannot predict the possibility of eradication of the
bacteria growing in biofilms w6x. The resistance against
antibiotics of biofilm growing bacteria can be due to
several factors such as slow growth, reduced oxygen
concentrations at the base of the biofilm, maybe a
penetration barrier based on binding of e.g. the positively
charged aminoglycosides to the negatively charged
alginate polymers, the presence of b-lactamase from the
bacteria, which cleaves andyor traps b-lactam-antibiotics
and overexpression of efflux pumps w3,7–11x. The
increased resistance of the biofilm growing bacteria
means that antibacterial therapy usually fails with
respect to eradication of the bacteria in the biofilm,
although the ordinary susceptibility tests in the labora-
tory demonstrate sensitivity to the antibiotics used.
However, the antibiotic treatment regularly leads to
temporary clinical improvement of the patient and lung
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function in parallel to the decrease of the number of
(planktonic) bacteria (CFU) in sputum w12,13x.
3. Traditional resistance mechanisms in P. aeruginosa
biofilms
The development of resistance to antibiotics occurs
frequently in CF due to the intensive selective pressure
provided by the large amount of antibiotics used in
these patients w14x. Mucoid and non-mucoid variants of
the same strain is frequently present in sputum simulta-
neously but the non-mucoid variants are more resistant
to antibiotics possibly reflecting a higher antibiotic
selection pressure out-side the alginate biofilm w15x. The
number of P. aeruginosa CFU in sputum may be as
high as 10 –10 yml. This implies that mutations occur8 10
in sputum. Actually, high frequency (36%) of hyper-
mutable P. aeruginosa has been found in CF lung
infection w16x. By means of population analysis of the
P. aeruginosa majority and minority populations as
regard to resistance to b-lactam antibiotics Giwercman
et al. w17x have shown, that at the onset of therapy the
majority of P. aeruginosa CFU in sputum was sensitive
to the antibiotics used for treatment, whereas a minority
of CFU already was resistant. The clonality of this
minority was identical to the sensitive majority popula-
tion. During therapy, however, the resistant minority
population took over and became predominant as a
consequence of the selective pressure imposed by the
antibiotic therapy w17x. In these studies the conventional
mechanism of resistance to b-lactam antibiotics was
shown to be partially due to depressed production of
chromosomal b-lactamase which could be further
induced w18x. Moreover, free b-lactamase activity, prob-
ably exported in liberated microvesicles w9x, could be
detected in CF sputum and the level increased to high
concentrations during the course of piperacillin, cefta-
zidime, cefsulodin and imipenem therapy w18x. Aztreon-
am therapy led to the opposite result because the
b-lactamase activity decreased and aztreonam was able
to mask b-lactamase activity by acting as an inhibitor
w18x. Double b-lactam therapy with aztreonam and e.g.
piperacillin, ceftazidime or meropenem is therefore a
rational approach.
Development of resistance to ciprofloxacin is regular-
ly seen w19x, and resistance to aminoglycosides is also
a problem in CF patients with chronic P. aeruginosa
infection, whereas resistance to colistin is seldom seen
in spite of a daily selective pressure in patients receiving
colistin by inhalation w14,20x. The high frequency of
hypermutable P. aeruginosa in CF w16x, the high level
of resistance to ciprofloxacin due to several different
mutations w19x and the induction of mutations by means
of oxygen radicals from PMNs leading to alginate
production w4x and the antioxidant imbalance in the CF
lung w21x have lead us to suggest, that it is the chronic
inflammation dominated by PMNs which induce high
level of mutations in P. aeruginosa in CF lungs and the
resistant mutants are then selected by the heavy use of
antibiotics. If this is true, antioxidant therapy with N-
acetylcystein w22x may be a new way to delay devel-
opment of conventional resistance to antibiotics in P.
aeruginosa in CF patients.
4. Therapeutic strategies for P. aeruginosa biofilms
A logical consequence of the resistant biofilms is to
aim at improved prophylaxis and early aggressive ther-
apy before the biofilm is fully established and before
the inflammatory reaction around the biofilm is recruit-
ed, leading to tissue damage and clinical symptoms w14x.
In this way it is possible to prevent or at least delay the
onset of the chronic P. aeruginosa infection in most CF
patients by early aggressive therapy of the intermittent
colonization with oral ciprofloxacin in combination with
colistin inhalation. Inhalation of tobramycin or genta-
micin has also been shown to be effective w14,23x. This
early, aggressive therapeutic approach is widely accepted
and has been published by a European CF consensus
conference w12–14x. Further improvement of this
approach may possibly be achieved by addition of
macrolides or N-acetylcystein, since early alginate pro-
duction characterizes therapeutic failures. It has recently
been shown that extracellular DNA is present in P.
aeruginosa biofilms and is essential for the early devel-
opment of the biofilm w24x. Furthermore, bovine DNase
I can completely inhibit the early development of P.
aeruginosa biofilm and, consequently, early prophylactic
use of DNase I in CF may therefore prevent the
establishment of chronic lung infection with these bac-
teria w24x.
Another logical consequence of the resistant biofilms
is to suppress the number and activity of the P. aerugi-
nosa bacteria in the lungs of CF patients using intrave-
nous tobramycin in combination with a b-lactam
antibiotic. This principle is called maintenance chemo-
therapy (chronic suppressive therapy or elective therapy)
w14x. This principle is therefore to restore lung function
repeatedly by regular 2 week courses of intensive
intravenous treatment every 3 months in the CF centre
or at home and, in addition, daily inhalations of colistin
between and during the courses of intravenous antibi-
otics and sometimes also by giving oral ciprofloxacin
between these courses. This treatment strategy has sig-
nificantly improved the survival of CF patients w14x.
Maintenance therapy with oral ciprofloxacin every 3
months is also efficient w14x. Frequent (3–4 times a
year) non-elective intravenous treatment of acute exac-
erbations of the chronic P. aeruginosa infection may
also be efficient w14x. Maintenance treatment with high
doses of inhaled tobramycin on–off every other months
is another effective approach, which is convenient for
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the patients w25x. The principles of maintenance therapy
is widely accepted and has been published by a Euro-
pean CF consensus conference w14x.
The mechanism of action of the antibiotics in the
chronic infection caused by biofilm growing P. aerugi-
nosa is not entirely clear. Although the biofilm mode of
growth is the characteristic feature of the infection,
planktonic bacteria susceptible to antibiotics also occur
plentifully in the lungs. In addition, in vitro studies have
shown that the number of biofilm growing bacteria can
be reduced to 20% by high doses of combinations of
antibiotics (piperacillinqtobramycin) w26x. Further-
more, sub-MIC concentrations of some antibiotics have
been shown to suppress the production of exoproducts
such as proteases and phospholipase C (see below) and
alginate of P. aeruginosa and colistin binds to LPS of
P. aeruginosa w27–29x. According to these results, there-
fore, the decrease of the CFU of planktonic bacteria and
to some degree of biofilm bacteria and the inhibition of
exoproducts will reduce the antigenic load in the lungs
and therefore probably also the concentration of immune
complexes. Accordingly, inflammatory parameters and
lung function improve during antibiotic therapy and in
this way it is possible to maintain the lung function of
the patients for years w12–14x. Further improvement of
this approach will focus on eradication of the biofilm.
5. Innovative approaches and potential therapies for
P. aeruginosa biofilms
New antibiotics and new ways of using old antibiotics
as indicated above are, however, needed due to the
development of resistance to those antibiotics currently
used in CF patients and in order to try to eradicate the
biofilm w30x. A new groups of promising agents is
peptide antibiotics, some of which are highly active
against P. aeruginosa and which hopefully may be
developed for inhalation therapy w31x. Another new
therapeutic approach may emerge from the synergism
described between some b-lactam antibiotics and spe-
cific phospholipids, which increase the permeability of
the P. aeruginosa outer membrane by binding both
Ca and Mg w32x. Aminoglycosides are bound to2q 2q
the alginate of the biofilm, but since alginate lyases can
facilitate the penetrations of these antibiotics by dissolv-
ing the alginate of the biofilm w33x a new therapeutic
approach may consist of inhalation of alginate lyases
and aminoglycosides. A new interesting principle used
to kill the biofilm growing bacteria, at least in vitro, is
a combination of antibiotics and electricity (DC, 10–20
V, 20 mA over a distance of 2.5 mm) w34x. This
combination kills the bacteria in the biofilm although
neither the antibiotic nor the electric current alone are
effective. Whether these promising new antibiotics and
principles will be adaptable to chronic pulmonary infec-
tion by P. aeruginosa in CF patients is uncertain.
Chronic suppressive therapy by means of long-term
daily macrolide therapy has significantly reduced symp-
toms and inflammatory parameters and increased the
survival of Japanese patients suffering from diffuse
panbronchiolitis and chronic P. aeruginosa lung infec-
tion w29x. In CF patients with chronic P. aeruginosa
infection a similar effect has been reported in a recent
controlled study using azithromycin 250 mgyday for 3
months w35x. The efficacy of macrolides in spite of their
lack of bacteriostatic or bacteriocidal effect against P.
aeruginosa is probably due to an anti-inflammatory
activity and a sub-MIC effect which inhibits the produc-
tion of proteins such as the exoproteases of P. aeruginosa
and inhibit and destroy the biofilm matrix w29x. Some
of the reason for this sub-MIC effect seems to be that
azithromycin and maybe other macrolides inhibit the
quorum sensing of P. aeruginosa w36x which is necessary
for maturation of the biofilm and which turn on the
genes which regulate the production of many virulence
factors of these bacteria. Other promising agents have
been detected in nature which inhibit quorum sensing
e.g. the halogenated furanones, which are produced by
the seaweed algae, Delisea pulchra, and these algae are
relatively free of surface colonization w37x. Such com-
pounds may also prevent or destroy P. aeruginosa
biofilms in the lungs of CF patients.
6. Anti-inflammatory therapy
Based on the concept of inflammation-mediated tissue
damage, several clinical trials of the use of anti-inflam-
matory drugs in CF patients have been carried out. Side
effects develop too frequently when systemic prednisone
is given w38x. Oral non-steroid anti-inflammatory agents
(ibuprofen, peroxicam) and inhaled budesonide have
been shown to have some efficacy in maintenance of
the lung function without serious side effects and are
now used routinely in some CF centres w39–41x.
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